Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma

Clinical Snapshot

Key Findings

• P Value: Not reported in abstract

• Effect Size: Overall response rate 98%, stringent complete response rate 55%

• Primary Outcome: Safety - no unexpected safety findings, no delayed neurotoxicity reported

• Nnt Or Sensitivity: 80% of evaluable patients achieved minimal residual disease negativity

• Confidence Interval: Not reported in abstract

Clinical Application

Rapid manufacturing platform (24 days) may improve patient access compared to traditional CAR T manufacturing Would require TGA approval and PBS listing; could be delivered through existing CAR T centres in major Australian hospitals; aligns with current RACGP referral pathways for haematological malignancies Heavily pretreated patients with relapsed/refractory multiple myeloma who have exhausted standard therapies

Abstract

Traditional manufacturing of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapies is prolonged, leading to reduced patient access, T cell exhaustion, and consequently limiting therapeutic efficacy. To address this issue, we developed durcabtagene autoleucel, a BCMA-directed CAR T cell therapy manufactured using a rapid platform aimed at preserving T cell stemness. Here, we present the primary findings of part A of a phase 1 study (NCT04318327) of durcabtagene autoleucel in patients with relapsed/refractory multiple myeloma (r/r MM). The primary objective was safety; secondary objectives included response rates, cellular kinetics, immunogenicity, and manufacturing feasibility. Durcabtagene autoleucel was successfully manufactured for all 55 patients (median vein-to-vein time, 24 days) and given as a single infusion at one of four flat target doses (2.5 × 106 to 20 × 106 CAR T cells). Among all patients, the overall response rate was 98%, and the stringent complete response rate was 55%. Eighty percent of evaluable patients (35 of 44) achieved minimal residual disease negativity. There were no unexpected safety findings and no reports of delayed neurotoxicity. Immunophenotyping and transcriptomic analyses confirmed preservation of a stem-like phenotype in the manufactured final product. On the basis of the safety, efficacy, and cellular expansion results from the phase 1 trial, a phase 2 trial (NCT05172596) was initiated to further explore the efficacy and safety of durcabtagene autoleucel in heavily pretreated patients with aggressive r/r MM.

References

1. 1.Sperling, A. S., Derman, B. A., Nikiforow, S., Alonso, A., Ikegawa, S., Orwitz, N., Quinn, D. S., Pearson, D., Bu, D., Milanez-Almeida, P., Mataraza, J., Nadeem, O., Liegel, J., D'Souza, A., Charles, A., Credi, M., Ritz, J., Jakubowiak, A. J., De Vita, S., & Munshi, N. C. (2026). Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adx1799